The humanization of monoclonal antibodies has generated a class of therapeutic products with improved safety, longer half-lives, and greatly diminished immunogenicity. These engineered proteins are highly species specific and in many cases only cross-react in humans. Where there is cross-reactivity in nonhuman primates or other species, it is not always clear that the pharmacologic effects reflect the potential actions in human volunteers or patients. As with other biologic products, the profile of humanized monoclonal antibodies dictates the preclinical strategy. The preclinical programs for the 2 humanized monoclonal antibodies described here, anti-HLA-DR (Hu1D10) and anti-CD3 (HuM291), demonstrate several unique aspects that affected their preclinical development strategy. Hu1D10 binds to a posttranslational form of HLA-DR and recognizes this antigen in some but not all human and nonhuman primates. The second antibody, HuM291, cross-reacts with CD3 only in the chimpanzee, which is not an optimal test species. In addition, a marketed anti-CD3 product exists (OKT3&reg;), and in the preclinical development of our antibody during testing of efficacy and safety, we needed to focus on adverse effects that might be similar to those of OKT3&reg;. In these studies, the safety, pharmacokinetics, immunogenicity, and pharmacology (B-and T-cell depletion and recovery) of the 2 antibodies were evaluated. The focus in this review is on the safety and pharmacology testing and the current status of each drug.
The murine anti-human antibody 1 D 10 is a monoclonal antibody prepared by immunization of mouse with human B lymphoma cells. It binds to a posttranslational form of HLA-DR. The antigen recognized by Lid 10 is an HLA-DR variant expressed on normal B cells and on Bcell lymphomas and leukemias in 60-90% of individuals. The humanized monoclonal anitbody HulDIO will be used to treat patients with B-cell tumors that are 1D10 antigen positive. The characterization of the murine antibody and the humanized version will be published elsewhere (M. Cole et al, in preparation) .
Although HulDIO induces antibody-dependent cytotoxicity, complement fixation, and apoptosis of B-cell tumor lines in vitro (J. Tso, unpublished observation), it was also important to demonstrate that Hu1D10 can deplete B cells in vivo and can be safely used in patients. The rhesus monkey was selected as an appropriate model to test safety and efficacy because HulDIO cross-reacts with rhesus monkey B cells.
However, among human volunteers and rhesus monkeys, HulDIO reacts with B cells in 20-70% of the dif-ferent subject populations tested (D. Hsu and J. Tso, unpublished observations). The expression level of the antigen on B cells varies over a wide range among individuals, which is clearly shown using flow cytometry (FACS) to determine mean fluorescence intensity (MFI) of Hu 1 D 10-fluorescein isothiocyanate binding on B cells. Based on MFI, the animals can be divided into 3 groups: strong positive, weak positive, and negative. Therefore, it was necessary to prescreen animals for 1D10 antigen expression prior to assigning them to the study.
Twelve HulDlO strong antigen-positive (Ag+) rhesus monkeys were divided into 3 groups (n = 4) and received bolus intravenous injections of I or 10 mg/kg of HulDlO or placebo. Animals were dosed daily for 5 consecutive days. Four HulDlO antigen-negative (Ag-) animals received 10 mg/kg with the same dosing regimen as the 4 HulDIO Ag+ animals. Animals were anesthetized prior to treatment, and drug was administered as a bolus intravenous injection.
Depletion of circulating B cells in these animals was monitored by measuring absolute counts of CD20+HLA-DR+ cells in the blood by FACS analysis. Both CD20 and HLA-DR are expressed on rhesus monkey B cells, and the anti-HLA-DR antibody used for fluorescence staining recognized an epitope distinct from that recog-nized by HuID10. Samples were collected at 0, 5, 60, and 360 min and on days 1, 2, 3, 4, 7, 14, 21, 28, 35, and 42. Blood samples were also taken for pharmacokinetics and immunogenicity studies.
B-cell depletion in 1D 10-positive animals was observed as soon as 5 min after administering the first dose of 1 or 10 mg/kg of the drug. At this time, an average of 75% of B cells in these animals had disappeared from the circulation. At 60 min after the first dose, only 10% of the B cells remained in the circulation. B-cell counts were slightly increased by 24 hr in most animals. However, continuous daily dosing of Hu 1 D 10 over the next 4 days maintained B-cell depletion at 3% and 9% of the predose level in the 10-mg and 1-mg groups, respectively. After completion of dosing, the average B-cell counts in the 10-mg group remained at 3-11 % of the predose level between days 7 and 14, and those in the 1 mg group remained at 16-23% during the same interval, suggesting a dose-related response. B-cell counts gradually recovered during the next several weeks. By day 42, B-cell counts in all dosed animals had recovered to about 20-50% of predose levels. B-cell depletion was not observed in either the led 10 Ag+ placebo group or the Lid 10 Aggroup that received multiple doses at 10 mg/kg. These results indicate that the B-cell depletion by Hu 1 D 10 in rhesus monkeys is antigen specific.
In addition to the pronounced biologic efficacy of Bcell depletion, Hu 1 D 10 precipitated unexpected adverse side effects characterized by an anaphylactic reaction that included respiratory suppression, increased heart rate, and urticaria; life-sustaining intervention was required in some animals. This acute reaction was seen in both dosage groups in a total of 5 of 8 Lid 10 Ag+ animals treated with Hu 1 D 10. None of the placebo animals or the led 10 Ag-animals experienced these adverse effects. There was a wide range of severity and persistence of symptoms in the treated Lid 10 Ag+ animals. Because of the rapidity and severity of these adverse effects, it was important to understand the etiology of the reactions and to seek methods to ameliorate the symptoms.
For many proteins and in particular large doses of antibodies, the rate of infusion is related to the incidence and severity of side effects (5) . In this instance, we suspected that anesthesia might have exacerbated the respiratory side effects. To test this hypothesis, 4 Ag+ animals were treated as described above but were infused with antibody over 90 min instead of 5 min and without anesthesia. The results confirmed that alteration of the dosing regimen and pretreatment with a mild antihistimine product (diphenhydramine) eliminated all of the side effects seen in the first study. The effect of Hu1D10 on Bcell depletion was not altered by the slower rate of infusion. Based on these results, a clinicaltrial program is being planned.
PRECLINICAL DEVELOPMENT STRATEGY FOR HuM291 1
HuM291 is a humanized IgG2a anti-CD3 monoclonal antibody that was engineered with specific mutations in the Fc domain to reduce its affinity for Fey receptors (2) (Cole et al, submitted). This designed mutation was intended to reduce the cytokine release syndrome (CRS) (1, 6) and the human antibody to monoclonal antibody (HAMA) response seen with the currently marketed product Orthoclone OKT3&reg;, an anti-CD3 murine monoclonal antibody (3, 4) . Compared with OKT3&reg;, HuM291 reduced cytokine secretion from human and chimpanzee peripheral blood mononuclear cells (PBMC) in vitro. To test HuM291 in vivo, our efforts were limited to the chimpanzee (Pan troglodytes) because it is the only nonhuman cross-reactive species. Our preclinical strategy was not only based on the known pharmacology of HuM291 but on the known preclinical and clinical effects of OKT3&copy; and other anti-CD3 agents in development.
Antibodies are typically species specific, and it would not be meaningful to test an antibody in an animal that did not express the target antigen. To establish an animal model for a particular antibody, it is necessary to test the cross-reactivity of antibody in question with the target antigen of the test species. To generate sources of the target CD3 antigen, chimpanzee, rhesus monkey, and baboon T-cell blasts were propagated by incubation of PBMCs from these animals with phytohemaglutanin (PHA) and interleukin (IL)-2. Binding of HuM291 to the CD3 antigens was then tested by FACS analysis. Among the 3 species of nonhuman primates examined, only chimpanzee T cells were recognized by HuM291.
HuM291 has been characterized in vitro using human PBMCs and is much less mitogenic to T cells than is OKT3&reg; in terms of inducing proliferation and production of cytokines such as tumor necrosis factor (TNF)-a., interferon (IFN)--y, and IL-2. Also in vitro, HuM291 downmodulates expression of CD3 on human T cells and blocks T-cell recognition to alloantigens in the mixed lymphocyte reaction (MLR) (Cole et al, submitted).
These same in vitro studies were also conducted using chimpanzee PBMCs to compare HuM291 to OKT3&reg;. The results indicate that HuM291 downmodulates CD3 expression on chimpanzee T cells to the same extent as does OKT3&reg;, and HuM291 is also much less mitogenic than OKT3&reg;. These data suggested that the chimpanzee is an appropriate model for the study of HuM291 for in vivo characterization.
Having identified an appropriate test species, the dose and dosing regimen was determined to reflect the targeted indication, such as acute allograft rejection, and the specific patient population. Given this indication and the current use of OKT3&reg; in patients, it was likely that multiple dose therapy would be needed for HuM291 in clinical settings. Prior to conduct of an Investigational New Drug multiple-dose study, a pilot single-dose-range study was performed to define the pharmacokinetics, the pharmacodynamics, and the effective dose range.
As end point evaluations, circulating T-cell number, cytokine (TNF-a, IFN-y, and IL-6) secretion, HuM291 serum concentration, and anti-HuM291 antibody levels in the circulation were measured. Eight healthy chimpanzees of both sexes weighing from 40 to 60 kg were used (n = 2 chimpanzees per dose). Animals were not previously exposed to human or murine antibodies and were dosed over a range of 1-10 mg HuM291 per animal.
Because of the known potential of anti-CD3 antibodies to stimulate cytokine secretion and to initiate CRS, vital signs were continuously monitored prior to administration of drug and for at least 2 hr after dosing.
To measure T-cell depletion, whole blood samples were collected at various time points through 11 wk. Absolute counts of CD2+/CD3+ T cells and total CD2+ T cells were measured by FACS analysis. The results showed that T-cell depletion occurred as early as I hr after a single dose in all HuM291 dose groups, and T cells were completely removed from peripheral circulation by 6 hr after dosing. The time for T-cell recovery was, however, dose dependent. T-cell counts gradually increased as the HuM291 serum concentration in circulation decreased, indicating that depletion was reversible.
CD3 downmodulation was not observed on the T cells remaining in circulation. In the placebo group, neither Tcell depletion nor CD3 downmodulation were observed. (The pharmacokinetics and primate anti-human antibody results are reported elsewhere.)
Based on the results of this single-dose pilot study, it was clear that a single dose of I or 10 mg was efficacious for T-cell depletion but without adverse side effects. However, T-cell depletion was transient, as expected, and a multiple-dose study was designed to evaluate the potential for prolonged T-cell depletion and recovery. In the multiple-dose study, animals were administered 0, 0.1, 1.0, and 10 mg per animal per dose. Animals in the 0-, 0.1-, and 1.0-mg dose groups received 6 doses (3 doses/ wk for 2 wk), and animals in the 10-mg group received a total of 3 doses (3 doses/wk for 1 wk). The dosing interval was selected based on the duration of T-cell depletion following single-dose administration in the pilot study. The results of this study have been described in detail elsewhere (D. Hsu et al, submitted).
T-cell depletion again occurred immediately (within 5 min) following all doses of HuM291, but only 10 mg induced a prolonged, complete depletion of circulating T cells. T-cell numbers recovered to near normal levels by about 28 days after the last dose of HuM291. Assays conducted to assess T-cell function (PHA stimulation and MLR) demonstrated normal functional properties of recovered T cells measured on days 0, 40, and 54. Therefore, HuM291 does not cause prolonged immune hyporesponsiveness or immunodeficiency in chimpanzees.
Animals treated with HuM291 in all dose groups demonstrated measureable levels of TNF-a, INF-~y and IL-6 by 2-6 hr after only the first dose of HuM291 (D. Hsu et al, submitted). There was no discemable dose-response effect because of the small group sizes and the interanimal variability. In spite of the substantial cytokine release and circulating levels, no clinical symptoms associated with cytokine release were observed. This finding suggests that the side effects associated with anti-CD3 therapy may not necessarily result directly from cytokine secretion or, alternatively, that chimpanzees may be less sensitive than humans to the toxicities of cytokine release and therefore may not be an ideal model for predicting CRS in humans.
Based on the immunomodulatory effects of HuM291 1 in chimpanzees, this antibody may mediate clinically beneficial immunosuppression in humans. In addition, because HuM291 is a humanized monoclonal antibody and has reduced mitogenic activity for human PBMC in vitro, HuM291 should be less likely than OKT3&copy; to stimulate T cells or to elicit an immune response when used clinically to treat acute allograft rejection. Initial clinical studies investigating the safety and pharmacology of HuM291 in human allograft recipients will be reported elsewhere (D. Norman et al, in preparation). These results will help determine the suitability of the chimpanzee as a model for predicting the pharmacology and toxicity of HuM291 in the clinic.
